跳至主要内容
临床试验/NCT06109259
NCT06109259招募中1 期

An Open-label, Randomized, 2x4 Crossover Study to Compare the Pharmacokinetics and Safety Following Administration of DWJ1567 and DWC202312 in Healthy Volunteers

Daewoong Pharmaceutical Co. LTD.1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2023年11月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
44
试验地点
1
主要终点
Cmax,ss of DWJ1567 and DWC202312

研究概览

简要总结

This study aims to compare the pharmacokinetics and safety following administration of DWJ1567 and DWC202312 in healthy volunteers

详细描述

The study design is a Randomized, Open-label, Oral, Single-dose, Four-way crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUCt of DWJ1567 and DWC202312. Secondary endpoints were AUCinf, Tmax, t1/2 of DWJ1567 and DWC202312.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Over 19 year old

排除标准

  • Galactose intolerance
  • Lapp lactase deficiency

研究组 & 干预措施

DWJ1567

Experimental

DWJ1567

干预措施: DWJ1567 (Drug)

DWC202312

Active Comparator

DWC202312

干预措施: DWC202312 (Drug)

结局指标

主要结局

Cmax,ss of DWJ1567 and DWC202312

时间窗: At pre-dose (0 hour), and post-dose 0 to 72 hour.

AUCt of DWJ1567 and DWC202312

时间窗: At pre-dose (0 hour), and post-dose 0 to 72 hour.

次要结局

  • AUCt/AUCinf of DWJ1567 and DWC202312(At pre-dose (0 hour), and post-dose 0 to 72 hour)
  • AUCinf of DWJ1567 and DWC202312(At pre-dose (0 hour), and post-dose 0 to 72 hour)
  • Tmax of DWJ1567 and DWC202312(At pre-dose (0 hour), and post-dose 0 to 72 hour)
  • t1/2 of DWJ1567 and DWC202312(At pre-dose (0 hour), and post-dose 0 to 72 hour)

研究者

发起方
Daewoong Pharmaceutical Co. LTD.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验